Kiniksa Pharmaceuticals International Plc Dossier
Qualitative Analysis
Business overview
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need, primarily in cardiovascular and autoimmune indications. The company's commercial engine is anchored by ARCALYST (rilonacept), an FDA-approved weekly subcutaneous injection that acts as an interleukin-1 alpha (IL-1̑) and interleukin-1 beta (IL-1̒) cytokine trap. ARCALYST is approved for the treatment of recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), and deficiency of IL-1 receptor antagonist (DIRA). Kiniksa is also advancing a clinical-stage pipeline, including KPL-387 (abrilimab), an investigational monoclonal antibody targeting the IL-1 receptor currently in Phase 2/3 development for recurrent pericarditis, and KPL-1161, a preclinical Fc-modified monoclonal antibody designed for quarterly subcutaneous dosing.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Maximizing the commercial opportunity of ARCALYST (rilonacept) for recurrent pericarditis by expanding physician adoption, increasing the breadth and depth of prescribing, and driving penetration into both multiple-recurrence and first-recurrence patient populations.
Expected impact: Sustained high-growth net product sales, with 2026 revenue guided to $930 million - $945 million, and maintaining annual positive cash flow.
Advancing KPL-387, an investigational fully human monoclonal antibody targeting IL-1R1, through a combined Phase 2/3 clinical trial in recurrent pericarditis to establish a monthly subcutaneous self-injection treatment option.
Expected impact: Expansion of the IL-1 inhibition market by offering a more convenient monthly dosing profile compared to existing weekly therapies.
Developing KPL-1161, an investigational Fc-modified monoclonal antibody IL-1 receptor antagonist, with a target profile of quarterly subcutaneous dosing.
Expected impact: Establishing a highly differentiated, ultra-long-acting therapeutic candidate in the immunology and cardiovascular pipeline.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Out-licensed the global rights to develop and commercialize vixarelimab, a fully human monoclonal antibody targeting OSMRβ, allowing Genentech to focus on fibrotic diseases while Kiniksa secures non-dilutive capital to fund its core cardiovascular pipeline.
Terms: Kiniksa received $100 million in upfront and near-term payments, and is eligible to receive up to approximately $600 million in clinical, regulatory, and sales-based milestones, plus royalties on annual net sales.
Granted Huadong exclusive rights to develop and commercialize ARCALYST and mavrilimumab in the Asia Pacific region (excluding Japan), expanding the global footprint of Kiniksa's lead assets.
Terms: Upfront payments, milestone eligibility, and royalties on net sales in the licensed territory.